{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:25:17Z","timestamp":1788452717501,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00105-026-05753-8","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:40:39Z","timestamp":1784803239000},"page":"576-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapie von mastzellvermittelten Angio\u00f6demen","Treatment of mast cell-mediated angioedema"],"prefix":"10.1007","volume":"77","author":[{"given":"Anna","family":"Smola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lochbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"5753_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17111499","volume":"17","author":"R Asero","year":"2024","unstructured":"Asero\u00a0R, Calzari\u00a0P, Vaienti\u00a0S, Cugno\u00a0M (2024) Therapies for Chronic Spontaneous Urticaria: Present and Future Developments. Pharmaceuticals 17:1499. https:\/\/doi.org\/10.3390\/ph17111499","journal-title":"Pharmaceuticals"},{"key":"5753_CR2","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.jaip.2023.02.022","volume":"11","author":"R Asero","year":"2023","unstructured":"Asero\u00a0R, Ferrer\u00a0M, Kocaturk\u00a0E, Maurer\u00a0M (2023) Chronic Spontaneous Urticaria: The Role and Relevance of Autoreactivity, Autoimmunity, and Autoallergy. J\u00a0Allergy Clin Immunol Pract 11:2302\u20132308. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5753_CR3","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1111\/bcp.15845","volume":"89","author":"BA Baldo","year":"2023","unstructured":"Baldo\u00a0BA (2023) MRGPRX2, drug pseudoallergies, inflammatory diseases, mechanisms and distinguishing MRGPRX2- and IgE\/Fc\u03b5RI-mediated events. Br J Clin Pharmacol 89:3232\u20133246. https:\/\/doi.org\/10.1111\/bcp.15845","journal-title":"Br J Clin Pharmacol"},{"key":"5753_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.iac.2024.07.001","volume":"44","author":"JS Bernstein","year":"2024","unstructured":"Bernstein\u00a0JS, Bernstein\u00a0JA, Lang\u00a0DM (2024) Chronic Spontaneous Urticaria: Current and Emerging Biologic Agents. Immunol Allergy Clin North Am 44:595\u2013613. https:\/\/doi.org\/10.1016\/j.iac.2024.07.001","journal-title":"Immunol Allergy Clin North Am"},{"key":"5753_CR5","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1016\/j.jaip.2023.05.033","volume":"11","author":"KW Chuang","year":"2023","unstructured":"Chuang\u00a0KW, Hsu\u00a0CY, Huang\u00a0SW, Chang\u00a0HC (2023) Association Between Serum Total IgE Levels and Clinical Response to Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis. J\u00a0Allergy Clin Immunol Pract 11:2382\u20132389.e3. https:\/\/doi.org\/10.1016\/j.jaip.2023.05.033","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5753_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/j.1365-2222.2012.03957.x","volume":"42","author":"MK Church","year":"2012","unstructured":"Church\u00a0MK, Maurer\u00a0M (2012) H1-antihistamines and urticaria: how can we predict the best drug for our patient? Clinical & Experimental Allergy 42:1423\u20131429. https:\/\/doi.org\/10.1111\/j.1365-2222.2012.03957.x","journal-title":"Clinical & Experimental Allergy"},{"key":"5753_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.0733","volume":"161","author":"A Gim\u00e9nez-Arnau","year":"2025","unstructured":"Gim\u00e9nez-Arnau\u00a0A, Ferrucci\u00a0S, Ben-Shoshan\u00a0M et\u00a0al (2025) Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria. JAMA Dermatol 161:679. https:\/\/doi.org\/10.1001\/jamadermatol.2025.0733","journal-title":"JAMA Dermatol"},{"key":"5753_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaci.2025.09.028","volume":"157","author":"AM Gim\u00e9nez-Arnau","year":"2026","unstructured":"Gim\u00e9nez-Arnau\u00a0AM, Szalewski\u00a0R, Hide\u00a0M et\u00a0al (2026) Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies. J\u00a0Allergy Clin Immunol 157:143\u2013154. https:\/\/doi.org\/10.1016\/j.jaci.2025.09.028","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"5753_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/bjd.14768","volume":"175","author":"S Guill\u00e9n-Aguinaga","year":"2016","unstructured":"Guill\u00e9n-Aguinaga\u00a0S, J\u00e1uregui Presa\u00a0I, Aguinaga-Ontoso\u00a0E et\u00a0al (2016) Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a\u00a0systematic review and meta-analysis. British Journal of Dermatology 175:1153\u20131165. https:\/\/doi.org\/10.1111\/bjd.14768","journal-title":"British Journal of Dermatology"},{"key":"5753_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaip.2025.11.038","volume":"14","author":"FI Hsu","year":"2026","unstructured":"Hsu\u00a0FI, Bernstein\u00a0JA, Chhiba\u00a0KD, Saini\u00a0SS (2026) Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond. J\u00a0Allergy Clin Immunol Pract 14:361\u2013372. https:\/\/doi.org\/10.1016\/j.jaip.2025.11.038","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5753_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","volume":"132","author":"A Kaplan","year":"2013","unstructured":"Kaplan\u00a0A, Ledford\u00a0D, Ashby\u00a0M et\u00a0al (2013) Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy. J\u00a0Allergy Clin Immunol 132:101\u2013109. https:\/\/doi.org\/10.1016\/j.jaci.2013.05.013","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"5753_CR12","doi-asserted-by":"publisher","DOI":"10.2165\/11591130-000000000-00000","author":"ER Kavosh","year":"2011","unstructured":"Kavosh\u00a0ER, Khan\u00a0DA (2011) Second-Generation H1-Antihistamines in Chronic Urticaria. Am J Clin Dermatol. https:\/\/doi.org\/10.2165\/11591130-000000000-00000","journal-title":"Am J Clin Dermatol"},{"key":"5753_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jaip.2013.06.003","volume":"1","author":"DA Khan","year":"2013","unstructured":"Khan\u00a0DA (2013) Alternative Agents in Refractory Chronic Urticaria: Evidence and Considerations on Their Selection and Use. J\u00a0Allergy Clin Immunol Pract 1:433\u2013440.e1. https:\/\/doi.org\/10.1016\/j.jaip.2013.06.003","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5753_CR14","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jama.2024.15568","volume":"332","author":"P Kolkhir","year":"2024","unstructured":"Kolkhir\u00a0P, Bonnekoh\u00a0H, Metz\u00a0M, Maurer\u00a0M (2024) Chronic Spontaneous Urticaria. JAMA 332:1464. https:\/\/doi.org\/10.1001\/jama.2024.15568","journal-title":"JAMA"},{"key":"5753_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer\u00a0M, Casale\u00a0TB, Saini\u00a0SS et\u00a0al (2024) Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. J\u00a0Allergy Clin Immunol 154:184\u2013194. https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"5753_CR16","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/all.16243","volume":"79","author":"M Maurer","year":"2024","unstructured":"Maurer\u00a0M, Kolkhir\u00a0P, Pereira\u00a0MP et\u00a0al (2024) Disease modification in chronic spontaneous urticaria. Allergy 79:2396\u20132413. https:\/\/doi.org\/10.1111\/all.16243","journal-title":"Allergy"},{"key":"5753_CR17","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/all.16598","volume":"80","author":"M Maurer","year":"2025","unstructured":"Maurer\u00a0M, Metz\u00a0M, Anderson\u00a0J et\u00a0al (2025) Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria. Allergy 80:2178\u20132186. https:\/\/doi.org\/10.1111\/all.16598","journal-title":"Allergy"},{"key":"5753_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2408792","volume":"392","author":"M Metz","year":"2025","unstructured":"Metz\u00a0M, Gim\u00e9nez-Arnau\u00a0A, Hide\u00a0M et\u00a0al (2025) Remibrutinib in Chronic Spontaneous Urticaria. New England Journal of Medicine 392:984\u2013994. https:\/\/doi.org\/10.1056\/NEJMoa2408792","journal-title":"New England Journal of Medicine"},{"key":"5753_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.anai.2024.05.020","volume":"133","author":"TK Min","year":"2024","unstructured":"Min\u00a0TK, Saini\u00a0SS (2024) The future of targeted therapy in chronic spontaneous urticaria. Ann Allergy Asthma Immunol 133:367\u2013373. https:\/\/doi.org\/10.1016\/j.anai.2024.05.020","journal-title":"Annals of Allergy, Asthma Immunology"},{"key":"5753_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1009-z","volume":"18","author":"S Pal Singh","year":"2019","unstructured":"Pal Singh\u00a0S, Dammeijer\u00a0F, Hendriks\u00a0RW (2019) Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer 18:79. https:\/\/doi.org\/10.1186\/s12943-019-1009-z","journal-title":"Mol Cancer"},{"key":"5753_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40629-020-00158-y","volume":"30","author":"J Ring","year":"2021","unstructured":"Ring\u00a0J, Beyer\u00a0K, Biedermann\u00a0T et\u00a0al (2021) Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update. Allergo J Int 30:1\u201325. https:\/\/doi.org\/10.1007\/s40629-020-00158-y","journal-title":"Allergo J Int"},{"key":"5753_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaci.2025.04.004","volume":"156","author":"D Wong","year":"2025","unstructured":"Wong\u00a0D, Waserman\u00a0S, Sussman\u00a0GL (2025) Endotypes of chronic spontaneous urticaria and angioedema. J\u00a0Allergy Clin Immunol 156:17\u201323. https:\/\/doi.org\/10.1016\/j.jaci.2025.04.004","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"5753_CR23","doi-asserted-by":"publisher","DOI":"10.3238\/PersPneumo.2018.03.09.02","author":"M Worm","year":"2018","unstructured":"Worm\u00a0M (2018) Anaphylaxie: Wie richtig handeln? Deutsches \u00c4rzteblatt Online. https:\/\/doi.org\/10.3238\/PersPneumo.2018.03.09.02","journal-title":"Deutsches \u00c4rzteblatt Online"},{"key":"5753_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/all.70210","author":"T Zuberbier","year":"2026","unstructured":"Zuberbier\u00a0T, Ansari\u00a0AHA, Abdul Latiff\u00a0AH et\u00a0al (2026) The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. Allergy. https:\/\/doi.org\/10.1111\/all.70210","journal-title":"Allergy"},{"key":"5753_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/ddg.14932_g","volume":"21","author":"T Zuberbier","year":"2023","unstructured":"Zuberbier\u00a0T, Altrichter\u00a0S, Bauer\u00a0S et\u00a0al (2023) S3-Leitlinie Urtikaria. Teil 2: Therapie der Urtikaria \u2013 deutschsprachige Adaption der internationalen S3-Leitlinie. J\u00a0Dtsch Dermatol Ges 21:202\u2013216. https:\/\/doi.org\/10.1111\/ddg.14932_g","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"5753_CR26","unstructured":"(2026) Fachinformation Remibrutinib."}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05753-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05753-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05753-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:03:39Z","timestamp":1788451419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05753-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5753"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05753-8","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Smola: Honorare f\u00fcr Vortr\u00e4ge\/Beratungen und\/oder finanzielle Unterst\u00fctzung, um an Konferenzen\/Weiterbildungsveranstaltungen teilzunehmen: BioCryst, Celltrion, CSL Behring, Novartis, Otsuka, Sanofi und Takeda. Principal Investigator f\u00fcr klinische Studien: Celldex. R.\u00a0Lochbaum: Honorare f\u00fcr Vortr\u00e4ge\/Beratungen und\/oder finanzielle Unterst\u00fctzung, um an Konferenzen\/Weiterbildungsveranstaltungen teilzunehmen: BioCryst, CSL Behring, KalVista, Otsuka, RG und Takeda. Principal Investigator f\u00fcr klinische Studien: Takeda; finanzielle Unterst\u00fctzung f\u00fcr Forschungsprojekte: Takeda; anteilige Finanzierung der Stelle durch das Basic Clinician Scientist Programm der Medizinischen Fakult\u00e4t des Universit\u00e4tsklinikums Ulm (CASCADE\u00a01.0).","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}